Q4_Full Presentation_2023

Q4_Full Presentation_2023l semaglutide 50 mg in Focused phase 3 trial programme ients k y endpoint: BW % ients incl. T2D k y endpoint: BW % • 200 patients incl. T2D • 44 week • Primary endpoint: BW % • 300 patients • 64 week • Primary endpoint : BW % 2023 2024 Novo Nordisk ® 2025Page 141Page 143